Nebido Will Emerge As Hypogonadism Treatment Leader, Indevus Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Indevus expects Nebido to acquire the majority of the injectable testosterone hypogonadism treatment market when it launches in the U.S., the company said in an Aug. 9 earnings call